Sanofi Stock Surges 72.99% in Trading Volume, Leads Market with 2.29 Billion Turnover

On April 22, 2025, Sanofi (SNY) saw a significant increase in trading volume, with a turnover of 2.29 billion, marking a 72.99% rise from the previous day. The stock price of Sanofi also rose by 1.81%, marking the third consecutive day of gains, with a total increase of 2.55% over the past three days.

Sanofi recently received FDA approval for Dupixent, a targeted therapy for chronic spontaneous urticaria (CSU) in patients aged 12 and older who remain symptomatic despite antihistamine treatment. This approval is based on phase 3 trials and represents a significant advancement for over 300,000 US patients with inadequately controlled CSU. Dupixent, a monoclonal antibody targeting type 2 inflammation, is developed in collaboration with Regeneron.

This approval marks the seventh indication for Dupixent, which is now approved for a range of chronic, debilitating atopic conditions driven by underlying type 2 inflammation. The FDA's decision to expand the approval of Dupixent to include patients with CSU is a positive development for Sanofi, as it adds to the drug's already impressive portfolio of approved indications.

Sanofi's strong financial foundation, robust profitability, and strategic product pipeline offer a positive outlook for the company. The approval of Dupixent for CSU is expected to contribute to Sanofi's revenue growth and strengthen its position in the pharmaceutical market. However, the company faces challenges in revenue growth and free cash flow, which may impact its stock performance in the short term.